Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... mg at 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were ...

    Research Article last updated 07/29/2014 - 12:12pm.

  2. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower ...

    Research Article last updated 04/24/2012 - 2:47pm.

  3. Therapy for aplastic anemia

    ... in the unrelated donor registry, including cord blood. He is red cell- and platelet transfusion -dependent. He has been recommended ...

    Research Article last updated 01/09/2012 - 10:58am.

  4. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... more and longer haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Costs and quality of life in patients with myelodysplastic syndromes.

    ... Journal Title:  Am J Blood Res Primary Author:  ... most MDS patients become anaemic, so as to require red blood cell transfusions. To investigate the costs and the impact on ...

    Research Article last updated 09/16/2013 - 8:45am.

  6. Paroxysmal nocturnal hemoglobinuria in pediatric patients.

    ... Journal Title:  Pediatr Blood Cancer Primary Author:  ... failure (N = 10); gross hemoglobinuria with isolated red cell anemia (N = 1); and jaundice , hepatitis, and ...

    Research Article last updated 12/12/2011 - 10:07am.

  7. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

    ... (AML). Most MDS patients eventually require transfusion of red blood cells for anaemia, placing them at risk of transfusional iron ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

    ... myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Iron overload in myelodysplastic syndromes: diagnosis and management.

    ... stem cell malignancies characterized by ineffective blood cell production. Many MDS patients are dependent on red blood cell (RBC) transfusions for symptomatic management of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Iron chelation therapy in myelodysplastic syndromes.

    ... requires treatment. Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are ...

    Research Article last updated 10/11/2011 - 5:58pm.